Kamada Ltd Down 5.42% To $6.03 After Earnings

Kamada Ltd (KMDA) surpassed earnings projections on 3/6/2024 for Q4 2023.

Analyst expectations for Kamada Ltd earnings per share (EPS) were at $0.05, with the company surpassing those estimates with a reported EPS of $0.09, leading to a positive surprise of $0 per share (80%). Kamada Ltd's earnings rose 29% year-over-year as the firm reported an EPS of $0.07 in its year-ago quarter. The positive annual growth shows the Healthcare company is performing well amid recent economic conditions.

Revenues were downbeat at $36.4 million. That represents a 19.82% decrease in revenues from the year-ago report and is 3.39% lower than consensus estimates set at $37.7 million.

The stock is down 5.42% to $6.03 after the report.

Despite Kamada Ltd reporting a decline in revenues, earnings increased signaling a rise in profit margins.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

InvestorsObserver gives the stock a Bearish Sentiment score at the moment based on recent trading.

Kamada Ltd has been a strong performer over the past few months, garnering a high Long-Term Technical Rank by InvestorsObserver of 93, putting Kamada Ltd in the top 25% of stocks. The firm was recently trading at a 52-week high of $6.53 on March 5, 2024 and set a 52-week low on October 31, 2023 at $4.08.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.